Cite
Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.
MLA
Benatar, Michael, et al. “Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.” EBioMedicine, vol. 108, Oct. 2024, p. 105323. EBSCOhost, https://doi.org/10.1016/j.ebiom.2024.105323.
APA
Benatar, M., Macklin, E. A., Malaspina, A., Rogers, M.-L., Hornstein, E., Lombardi, V., Renfrey, D., Shepheard, S., Magen, I., Cohen, Y., Granit, V., Statland, J. M., Heckmann, J. M., Rademakers, R., McHutchison, C. A., Petrucelli, L., McMillan, C. T., & Wuu, J. (2024). Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis. EBioMedicine, 108, 105323. https://doi.org/10.1016/j.ebiom.2024.105323
Chicago
Benatar, Michael, Eric A Macklin, Andrea Malaspina, Mary-Louise Rogers, Eran Hornstein, Vittoria Lombardi, Danielle Renfrey, et al. 2024. “Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.” EBioMedicine 108 (October): 105323. doi:10.1016/j.ebiom.2024.105323.